Fig. 3. Subgroup analyses of MDSs with mutated TP53. (A) Kaplan–Meier curves of overall survival were plotted for MDS with mutated TP53^ICC and MDS/AML with mutated TP53^ICC. The HR and 95% CI were calculated using a multivariate Cox regression model adjusted for sex, age, ontogeny, diagnosis, and treatment. Within MDS-biTP53^WHO, Kaplan–Meier curves of overall survival were plotted according to (B) the type of biallelic TP53 inactivation and (C) VAF of TP53 mutations (whether the ICC diagnoses are MNs with mutated TP53 or not). The HR and 95% CI were calculated using a multivariate Cox regression model adjusted for sex, age, ontogeny, treatment, type of biallelic TP53 inactivation, and VAF of TP53 mutations. (D) Within MDS cases with ≥10% blasts, Kaplan–Meier curves of overall survival were plotted in MDS-IB2^WHO|MDS/AML^ICC, MDS-IB2^WHO|MDS/AML with mutated TP53^ICC, and MDS-biTP53^WHO|MDS/AML with mutated TP53^ICC. The HR and 95% CI were calculated using a multivariate Cox regression model adjusted for sex, age, ontogeny, treatment, and diagnosis. The HR is shown with the 95% CI in parentheses.
Abbreviations: ICC, International Consensus Classification; cnLOH, copy-neutral loss of heterozygosity; TP53_mut, TP53 mutations; VAF, variant allele frequency; MNs, myeloid neoplasms;. -IB2, with increased blasts-2, -biTP53, with biallelic TP53 inactivation; HR, hazard ratio; CI, confidence interval.

Ann Lab Med 2025;45:36~43 https://doi.org/10.3343/alm.2024.0079